Prof Nicolas Girard speaks to ecancer at ESMO 2024 about the results from the RELATIVITY-104 study.

This study evaluated nivolumab plus relatlimab with platinum-doublet chemotherapy versus nivolumab with platinum-doublet chemotherapy as first-line treatment for stage IV or recurrent non-small cell lung cancer.

Dr Girard reports that the addition of relatlimab to nivolumab with platinum-doublet chemotherapy led to an imprved clinical benefit in the form of an improved overall response rate.

There was particular benefit in the PD-L1 ≥ 1% and NSQ pre-specified subgroups.